Tempus AI, Inc. (TEM) Return on Equity (ROE): -72.74%
Is Tempus AI, Inc.’s return on equity (ROE) high or low?
Tempus AI, Inc.'s return on equity (ROE) of -72.74% is 63% above its 5-year average of -198.08%, near the high end of its 5-year range (-1252.79%–40.91%).
As of Friday, June 12, 2026. 88.83% above its 12-month average of -651.33%.
TEM Return on Equity (ROE) Chart
TEM Average Return on Equity (ROE) Chart
TEM Current vs Average Return on Equity (ROE) Chart
TEM Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-72.74%
RETURN ON EQUITY (ROE) AVG TTM
-651.33%
RETURN ON EQUITY (ROE) AVG 3Y
-315.37%
RETURN ON EQUITY (ROE) AVG 5Y
-198.08%
RETURN ON EQUITY (ROE) AVG 10Y
-163.33%
RETURN ON EQUITY (ROE) AVG 15Y
-163.33%
RETURN ON EQUITY (ROE) AVG 20Y
-163.33%
CURRENT VS TTM AVG
+88.83%
CURRENT VS 3Y AVG
+76.94%
CURRENT VS 5Y AVG
+63.28%
CURRENT VS 10Y AVG
+55.46%
CURRENT VS 15Y AVG
+55.46%
CURRENT VS 20Y AVG
+55.46%
TEM Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | -72.74% | -651.33% | -315.37% | -198.08% |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | -6.28% | -2.13% | 6.32% | 9.65% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 2.46% | -8.94% | -15.72% | 1.14% |
| Baxter International Inc. (BAX) | $10.58B | -18.17% | -12.46% | -8.76% | -1.37% |
| Hims & Hers Health, Inc. (HIMS) | $6.19B | -2.97% | 25.09% | 5.57% | 0.40% |
| Align Technology, Inc. (ALGN) | $12.27B | 10.36% | 10.54% | 10.84% | 19.93% |
| Solventum Corporation (SOLV) | $13.72B | 28.82% | 23.51% | 17.50% | 13.68% |
| Hologic, Inc. (HOLX) | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| 23andMe Holding Co. (ME) | $15.31M | -721.75% | 348.35% | 157.32% | 61.09% |
| Moderna, Inc. (MRNA) | $18.71B | -43.12% | -32.64% | -13.90% | 0.25% |
Return Analysis
ROE
-72.7%
ROA
-14.2%
Tempus AI, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Tempus AI, Inc. (TEM)?
- The return on equity (ROE) for TEM stock is -72.74%.
- Is Tempus AI, Inc.'s return on equity (ROE) high or low?
- Tempus AI, Inc.'s return on equity (ROE) of -72.74% is 63% above its 5-year average of -198.08%, near the high end of its 5-year range (-1252.79%–40.91%).
- What is the TTM average return on equity (ROE) for Tempus AI, Inc. (TEM)?
- The TTM average return on equity (ROE) for TEM stock is -651.33%.
- What is the 3Y average return on equity (ROE) for Tempus AI, Inc. (TEM)?
- The 3Y average return on equity (ROE) for TEM stock is -315.37%.
- What is the 5Y average return on equity (ROE) for Tempus AI, Inc. (TEM)?
- The 5Y average return on equity (ROE) for TEM stock is -198.08%.
- What is the 10Y average return on equity (ROE) for Tempus AI, Inc. (TEM)?
- The 10Y average return on equity (ROE) for TEM stock is -163.33%.
- What is the 15Y average return on equity (ROE) for Tempus AI, Inc. (TEM)?
- The 15Y average return on equity (ROE) for TEM stock is -163.33%.
- What is the 20Y average return on equity (ROE) for Tempus AI, Inc. (TEM)?
- The 20Y average return on equity (ROE) for TEM stock is -163.33%.
Tempus AI, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -49.87% |
| 2024-12-31 | -1252.79% |
| 2023-12-31 | 15.49% |
| 2022-12-31 | 25.67% |
| 2021-12-31 | 32.10% |
| 2020-12-31 | 40.91% |
| 2019-12-31 | 45.18% |
Related Metrics
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky